Valuation: argenx SE

Market Cap 58.56B 53.33B 49.14B 44.7B 83.86B 5,422B 88.14B 598B 238B 2,962B 220B 215B 9,295B P/E 2026 *
31.7x
P/E 2027 * 26.4x
Enterprise Value 54.78B 49.9B 45.98B 41.82B 78.46B 5,073B 82.46B 560B 222B 2,771B 206B 201B 8,696B EV / Sales 2026 *
8.45x
EV / Sales 2027 * 6.6x
Free-Float
100%
Yield 2026 *
0.07%
Yield 2027 * 0.11%
1 day-0.63%
1 week-2.91%
Current month+5.65%
1 month+8.42%
3 months-5.45%
6 months+20.76%
Current year+18.97%
1 week 849.6
Extreme 849.6
892.2
1 month 771.2
Extreme 771.2
896
Current year 568.4
Extreme 568.4
925
1 year 568.4
Extreme 568.4
925
3 years 271
Extreme 271
925
5 years 224.1
Extreme 224.1
925
10 years 13.25
Extreme 13.25
925
Manager TitleAgeSince
Chief Executive Officer 47 06/05/2026
Director of Finance/CFO 56 01/06/2021
Chief Tech/Sci/R&D Officer - 01/01/2015
Director TitleAgeSince
Chairman 54 06/05/2026
Director/Board Member 76 13/05/2015
Director/Board Member 65 28/04/2016
Date Insider Type Main position Quantity % Market Cap. Importance
11/23/25 A Sell

Chief Executive Officer

2,000 0.0032%
11/23/25 A Sell

Director

4,680 0.0076%
11/23/25 A Exercice

Director

4,680 0.0076%
Change 5-day change 1-year change 3-year change Capi.($)
-0.63%-2.91%+6.55%+89.34% 58.56B
-2.49%-3.76%+53.38%+62.10% 63.66B
-2.37%-2.22%+21.77%+84.58% 54.19B
-2.19%-6.15%+12.43%+111.40% 44.66B
-1.89%-7.28%+9.30%+18.50% 40.51B
-0.93%-0.47%+19.34%+41.83% 36.27B
+1.11%-6.44%+127.46%+675.37% 34.87B
-0.80%+0.61%+76.27%+61.80% 32.26B
-2.17%+16.65%-28.89%+479.93% 31.01B
-6.57%-12.37%+34.03%-15.63% 21.45B
Average -1.89%-2.33%+33.16%+160.92% 42B
Weighted average by Cap. -1.74%-2.39%+31.94%+146.36%

Financials

2026 *2027 *
Net sales 6.48B 5.91B 5.44B 4.95B 9.29B 600B 9.76B 66.23B 26.33B 328B 24.33B 23.82B 1,029B 7.98B 7.27B 6.7B 6.09B 11.43B 739B 12.01B 81.49B 32.39B 404B 29.93B 29.3B 1,266B
Net income 1.82B 1.66B 1.53B 1.39B 2.61B 168B 2.74B 18.58B 7.39B 92.01B 6.83B 6.68B 289B 2.14B 1.95B 1.8B 1.64B 3.07B 199B 3.23B 21.91B 8.71B 108B 8.05B 7.88B 340B
Net Debt -3.77B -3.44B -3.17B -2.88B -5.4B -349B -5.68B -38.54B -15.32B -191B -14.16B -13.86B -599B -5.93B -5.4B -4.98B -4.53B -8.5B -549B -8.93B -60.6B -24.09B -300B -22.26B -21.79B -942B
Projected Income Statement - Annual - argenx SE
Logo argenx SE
argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises.
Employees
1,863
Date Price Change Volume
20/11/26 €852.80 -0.63% 83,546
19/11/26 €858.20 -0.14% 64,870
18/11/26 €859.40 +0.59% 69,332
17/11/26 €854.40 -2.64% 111,065
16/11/26 €877.60 -0.09% 86,832
Trader
Investor
Global
Quality
ESG MSCI
A
MarketScreener Ratings - argenx SE
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
936.32USD
Average target price
1,117.67USD
Spread / Average Target
+19.37%
  1. Stock Market
  2. Stocks
  3. ARGX Stock